Person: IRMAK, SEÇİL
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
IRMAK
First Name
SEÇİL
Name
2 results
Search Results
Now showing 1 - 2 of 2
Publication Open Access Comparison of treatment durations before Covid-19 pandemic, pre- and post-vaccination periods in acute ischemic stroke patients in a Turkish tertiary hospital(2023-01-01) VURAL, EZGİ; ERDEM, SEMA NUR; IRMAK, SEÇİL; MİDİ, İPEK; Baran G., VURAL E., Erdem S. N., IRMAK S., Cetin S. Z., MİDİ İ.Objective: This study aimed to compare the frequency of admission to hospital in patients with acute ischemic stroke before the COVID 19 pandemic, during the pre-vaccination period, and after the start of vaccination for COVID 19, and to evaluate the time window period between symptom onset to door time, door to CT scan time, door to needle time, and door to puncture time. In addition, it aimed to investigate the effects of the COVID-19 pandemic on the admission, evaluation, and initiation of acute treatment of patients with acute ischemic stroke. Methods: Patients presenting with acute ischemic stroke between March 2019-December 2019 (pre-pandemic), March 2020-December 2020 (pre-vaccination pandemic period), and March 2021-December 2021 (post-vaccination pandemic period) were included in the study. NIHSS was calculated by accordance with the neurological examination findings of the patients, cranial CT for the exclusion of bleeding and CT angiography images for the large vessel occlusions were performed, and the vital signs of the patients were recorded. IV tPA treatment was applied within the first 4.5 hours, and mechanical thrombectomy (MT) was performed in patients with large vessel occlusion. Results: Three hundred nineteen patients were included in the study. The times from symptom onset to emergency admission and from symptom onset to CT scan were found to be similar in all periods. The time from symptom onset to examine by a neurologist was found to be significantly longer in the vaccination period compared to the pandemic period. It was observed that the time from the door to needle time and the time from examine by a neurology doctor to needle time was statistically significantly shorter during the pandemic period (p<0.05). Conclusion: In our study in a tertiary hospital in Turkey, it was determined that the number of patients who was admitted with acute stroke clinic during the pandemic period was similar to other years and there was no delay in the initiation of treatment during the pandemic period. Door to needle times, as well as the time taken by the neurologist to examine and initiate IV-tPA treatment, were found to be shorter in the pre-vaccination pandemic period than in the pre-pandemic and post-vaccination periods.Publication Metadata only Perceived stress associated With covid-19 in patients with neuro-Behcet's disease(2023-09-05) MİDİ, İPEK; IRMAK, SEÇİL; MİDİ İ., Gencel A., Sahin H., Mertoglu F., Bicer F. B., Akbas Z., IRMAK S.Since the end of 2019, COVID-19 has been a source of stress for many people. While some were afraid of getting sick and being hospitalized, others experienced financial hardships (eg, loss of employment) and pandemic-related stressors. Quarantines also had negative psychological effects during the pandemic. The objective of this study was to assess perceived stress associated with the COVID-19 pandemic in patients with neuro-Behçet’s disease with the Turkish version of the Perceived Stress Scale (PSS).1,2 METHODS Fifty-four patients diagnosed with neuro-Behçet’s disease according to the international Behçet’s diagnostic criteria3 by clinical and imaging methods were included in the study. The questionnaire was administered between February and March 2021. Study participants were contacted by phone due to the pandemic. The questionnaire collected demographics and characteristics of the patients, as well as duration of Behçet’s disease and neuro-Behçet’s diagnosis, current medications, and family history of Behçet’s disease. The survey included questions about COVID-19 infection to assess disease severity and whether a condition requiring hospitalization had developed. The status of neuro-Behçet’s disease during the pandemic and whether there was any disruption in their outpatient follow-up were also assessed. The PSS is a widely used psychological instrument for measuring the perception of stress. It was designed to determine how stressful an individual perceives certain life situations. The scale consists of 14 items scored between 1 and 5, with a total score ranging from 0 to 56. The PSS was applied to evaluate the stress levels of the patients in the last month. A high score indicates that the patient’s perception of stress is high.4 RESULTS Of 54 patients, 47% were male (n = 25) and 53% were female (n = 29). The mean age of the patients was 41.9 years. Seventeen patients had a family history of Behçet’s disease. The mean duration of Behçet’s disease and neuro-Behçet’s disease was 12 and 8.9 years, respectively. It was observed that neurologic involvement occurred 2.48 years after the diagnosis of Behçet’s disease. The mean PSS score of the patients participating in the study was 25.17. The mean ± SD PSS score was 30 ± 12.5 for female patients and 21.3 ± 13.3 for male patients (P = .019). Twelve of 54 patients had previously tested positive for COVID-19. These patients were not positive when they completed the questionnaire, and there was no statistically significant difference in PSS scores for patients with and without COVID-19 (P = .577) (Table 1). Fifteen of 54 patients had an “attack” described as a clinical worsening related to Behçet’s disease during the pandemic, and their mean ± SD PSS score was 29.65 ± 12.50. On the other hand, 39 of 54 patients had a stable or better course for Behçet’s disease, and their mean ± SD PSS score was 24.31 ± 13.71. We found that PSS score was not related to disease course (P = .140). There was no significant difference between the years of diagnosis of Behçet’s disease (P = .132) and neuro-Behçet’s (P = .129), comorbidities (diabetes mellitus: P = .445, hypertension: P = .294, coronary artery disease: P = .901, hyperlipidemia: P = .461), and PSS scores.